Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07547553RecruitingPhase 1/Phase 2
HH-009 for Advanced Liver Cancer with FGF19 Marker
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
Bengbu, AnhuiAges 18–75 - NCT07574671Recruiting
Ketogenic Diet Study for Early-Stage Breast Cancer
This study tests whether a ketogenic diet (high fat, low carb) can help change the environment around breast cancer tumors in ways that might slow cancer growth. You'll follow the diet for several months while researchers monitor your health and take measurements.
San Antonio, TexasAges 18 years+ - NCT07578064RecruitingPhase 4
Comparing two treatments for low white blood cells during breast cancer therapy
This study compares two medications—Shengbai Oral Liquid and Leucogen Tablets—to help raise white blood cell counts in breast cancer patients whose counts drop during cancer treatment. Both drugs aim to help your body recover faster and allow you to continue your cancer therapy on schedule.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07603544Recruiting
Hair Loss Study: Understanding Male Pattern Baldness
This research study examines what causes male pattern baldness (androgenetic alopecia) by studying hair, skin, and biological samples from men with hair loss and healthy men. The goal is to better understand why hair loss happens so scientists can develop better treatments.
Xinxiang, HenanAges 20–65 - NCT07615491Recruiting
Safety and effectiveness study of spinal implants and bone materials
This study tracks how well spinal implants (Titania systems) and bone-filling materials (BONEGRAFT) work after surgery and whether patients experience any problems. Researchers will follow patients after cervical or lower spine surgery to confirm these devices are safe and effective in real-world use.
IzmirAges 18 years+ - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT07623850RecruitingPhase 1
Early Study of JLM019 Injection for Advanced Cancers
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07656090Enrolling by invitationEarly Phase 1
Testing IDOV-Immune for advanced solid tumors
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07046832Enrolling by invitation
Augmented reality needle guidance for soft tissue biopsy
This trial tests a new augmented reality system that helps guide the needle during a soft-tissue biopsy. It may make the procedure more accurate and easier for your doctor.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06674538Enrolling by invitationPhase 1
Antibody trial for advanced solid tumors
This trial tests an antibody treatment for people with stage IV cancer that has not responded to previous treatment. It aims to find a new option for patients with several types of advanced solid tumors.
Hershey, PennsylvaniaAges 18 years+ - NCT06584877Enrolling by invitation
Understanding how childhood tumors and birth conditions start
This study looks at leftover tissue samples from children who have had tumors or birth conditions. Researchers want to learn more about how these conditions develop, and you may help if you or a relative fits the criteria.
CambridgeAges Any age - NCT06434376Enrolling by invitationEarly Phase 1
Personalized immune therapy for ctDNA-positive colorectal cancer
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
Wenzhou, ZhejiangAges 18–80 - NCT05160480Enrolling by invitation
Total-body PET scan using FDA-approved tracers for prostate or NET cancer
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Sacramento, CaliforniaAges 18 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT03610906Enrolling by invitation
Study of blood/tissue targets in suspected childhood brain tumors
This study looks at biological “targets” (things in the body) to help guide future medical treatments for children and teens with suspected craniopharyngioma. It will collect and analyze tissue samples from planned care to understand what therapies might work best.
Aurora, ColoradoAges 4 weeks–21 years - NCT03054792Enrolling by invitationPhase 1
MRI test to map low-oxygen areas in childhood sarcomas
This Phase 1 study uses special MRI scans to look at “low-oxygen” parts of a childhood sarcoma. It aims to help doctors better understand the tumor before standard treatment that may include chemotherapy and sometimes radiation.
Toronto, OntarioAges 6–18
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,319 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.